The story of Sildenafil presents a complex picture for investors. While the initial release generated massive gains, the end of its exclusive rights opened the floodgates to generic versions, dramatically eroding https://sahilxazb551201.blogoscience.com/48547427/the-copyright-and-big-pharma-a-volatile-opportunity